Pethema registry
Web5. nov 2024 · Here, we compared clinical outcomes between AZA and DEC in AML patients not eligible for intensive chemotherapy in the epidemiologic PETHEMA registry. Methods: We included newly diagnosed AML patients treated with AZA (75 mg/m2/d IV or SC days 1-7) or DEC (20 mg/m2/d IV days 1-5) that were not eligible for intensive chemotherapy.
Pethema registry
Did you know?
Web13. nov 2024 · We aim to compare retrospectively results of the PLERIFLAG cohort versus historical cohorts of patients salvaged with FLAG-IDA (Fludarabine, Idarubicine, Cytarabine, G-CSF as priming agent), or FLAGO-IDA (Gemtuzumab plus FLAG-IDA) registered in the PETHEMA epidemiologic AML registry (NCT02006004). Webon behalf of the PETHEMA Group This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)...
Web17. feb 2024 · The PETHEMA AML registry (NCT02607059) includes patients diagnosed with AML, regardless of the treatment administered. Patient and disease characteristics, … Web21. máj 2024 · The characteristics of new 11 variant APL cases registered by the PETHEMA group are in line with prior reports (male predominance, PLZF-RAR α as more frequent …
Web6. jún 2024 · Patients with age 60 years or above (older) reported to the multicenter and multinational PETHEMA APL registry are required to be diagnosed with APL with a demonstration of the t(15;17) or PML ... Web13. okt 2015 · March 22, 2024 updated by: PETHEMA Foundation Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2015) Epidemiologic …
WebName days are a big deal in Greece, often celebrated with more fanfare than birthdays – especially if one has a common name. For instance, on August 15th, when the Dormition …
WebHere, we compared clinical outcomes between AZA and DEC in AML patients not eligible for intensive chemotherapy in the epidemiologic PETHEMA registry. Methods: We included newly diagnosed AML patients treated with AZA (75 mg/m2/d IV or SC days 1–7) or DEC (20 mg/m2/d IV days 1–5) that were not eligible for intensive chemotherapy. iowa electric utility mapWeb6. dec 2006 · Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted … opal polishWeb9. máj 2024 · lignas (PETHEMA) epidemiologic registry. We also aim to evaluate the potential predic‐ tors associated with response and OS with each drug. 2. Patients and Methods 2.1. PETHEMA Registry The PETHEMA registry (NCT02607059) is an epidemiological registry of adult pa‐ tients with newly diagnosed AML. opal pokemon sword quizWebParent Technology Help - PrepNet Schools. 1 week ago Web NHA's Parent Relations Team Any questions related to Parent Portal can be directed to NHA's parent relations team at … opal powder for inlayWeb5. nov 2024 · Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry. Pilar Martínez, MD, *, 1 Tomás Palanques Pastor, *, 2 Jose Luiz Lopez Lorenzo, MD, *, 3 Javier Cornago Navascués, MD, *, 4 Gabriela Rodriguez-Macías, ... iowa electric.govWeb29. mar 2024 · para el Tratamiento de las Hemopatías Malignas (PETHEMA) epidemiologic registry. 2. Materials and Methods 2.1. Study Design and Patients The PETHEMA AML registry (NCT02607059) includes patients diagnosed with AML, regardless of previous treatments. We retrospectively collected the main patient charac-teristics, treatment … opal powder in tanning lotionsWeb29. mar 2024 · The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was … opal polycarbonat